News

An experimental vaccine in the United States has successfully moved to the final stage of testing

PHOTO CREDITS: ISTOCK IMAGES

According to The Associated Press, an experimental vaccine in the United States has successfully moved to the final stage of testing. The experimental vaccine, called mRNA-1273, was developed by scientists and researchers at the National Institutes of Health and Moderna Inc. and will start the final step of testing around July 27. This step includes a 30,000-person study to prove if the vaccination is strong enough to protect against the coronavirus. “No matter how you slice this, this is good news,” Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told The Associated Press. ~

On Tuesday, July 14, researchers received results from a previous study of the vaccination done on forty-five volunteers. Started in early March, the study required two doses of the vaccine, each a month apart. The study showed that the vaccine provided an immune boost for the volunteers and developed neutralizing antibodies in their bloodstreams at levels comparable to those found in people who survived COVID-19, the research team reported in the New England Journal of Medicine. The study reported no serious side effects from the vaccination, but more than half of the participants reported fatigue, headache, chills, or pain at the injection site, according to the National Institutes of Health. Systemic adverse events were more common following the second vaccination and in those who received the highest vaccine dose. The researchers noted that these symptoms often lasted only a day and occur immediately following the vaccination. “Small price to pay for protection against COVID,” said Dr. William Schaffner of Vanderbilt University Medical Center, a vaccine expert who wasn’t involved with the study. ~

The United States government hopes to have results of this vaccination by the end of the year – record-setting speed for developing a vaccine. Schaffner called the early results “a good first step,” and is optimistic that final testing could deliver answers about whether it’s safe and effective by the beginning of next year (AP). “It would be wonderful. But that assumes everything’s working right on schedule,” Schaffner cautioned. ~ 

ARTICLE: KYLE SMITH

Leave a Reply